While everyone's arguing about frontier models and trillion-dollar IPOs, an Indian company quietly did something this week that deserves far more attention. On September 18, Qure.ai Aira — a clinical decision support system (CDSS) from the Mumbai and New York-based company — received Class IIb CE certification under the EU Medical Device Regulation. That places it among the world's first AI-powered CDSS to combine documentation, workflow automation, patient EHR analysis and clinical decision-making under a single CE mark. Let that sink in: an AI system built by an Indian team, cleared under one of the world's strictest medical device frameworks.
01.What Aira actually does
Aira isn't a chatbot that answers health questions. It's built for frontline primary care — the busy government hospital OPD, the overloaded PHC, the health worker managing dozens of patients a day with paper records. Launched at the World Health Assembly in 2025, it sits as an AI layer on top of existing health systems and does three things: it turns consultations and paper records into a digital care trail, it equips health workers with patient history and national guideline-based recommendations, and it keeps contact with patients between visits instead of losing them to follow-up.
The design brief reads like a list of real-world Indian healthcare problems: it works in local languages, runs on existing digital devices, and stays functional on unreliable connectivity. Digitisation becomes part of care delivery rather than one more task for an overstretched worker — which, if you've ever watched an ASHA worker fill registers by hand, is exactly the right problem to solve.
02.Why Class IIb CE certification is a big deal
For those who don't follow medical device regulation (and honestly, why would you), the EU MDR is one of the most demanding regulatory frameworks on earth. Class IIb is the higher-risk tier — devices where a wrong output can seriously affect treatment decisions. Getting through it means demonstrating clinical validity and safety to independent notified bodies, not just running a nice demo.
Qure.ai's co-founder and CEO Prashant Warier put it plainly: "The quality of primary care a person receives should not be decided by their postcode. Class IIb certification is an important milestone because it validates our clinical decision support within one of the world's most rigorous medical device regulatory frameworks." In plain terms — European regulators have now effectively signed off on this system making clinical recommendations. That's not a marketing badge; it's a door opener for hospitals across Europe and anywhere that trusts CE marking.
03.A decade of quiet Indian work behind this
Here's the part I find most satisfying. Qure.ai isn't an overnight success — it has spent close to a decade doing the unglamorous work of regulated medical AI, starting with TB and lung cancer screening. Today the company's broader portfolio is deployed across more than 105 countries, with 26+ FDA-cleared findings and CE marking for over 60 indications. It was named a TIME100 Most Influential Company in 2025. And in its first year, Aira alone has scaled to ten live pilot sites reaching thousands of patients across Nigeria, Kenya, Mozambique, Solomon Islands and Bangladesh.
This is the second big Indian AI-in-healthcare story in a single week — we wrote about Kardi Ai's AI-powered ECG monitoring launching in Hyderabad earlier today, and before that, AIIMS' mammogram-reading AI built entirely on Indian data. A pattern is forming, and it's a good one: Indian teams building for Indian problems first, then exporting globally. And if stories like this make you want to build something of your own, the GPT-6 Astra — Zero to Hero Guide we publish includes a full chapter on AI business ideas, including healthcare, plus cost optimization worksheets.
04.What this means for Indian healthcare
India's primary care system runs on an enormous but overstretched workforce. A CDSS that documents, reminds, follows up and recommends according to national guidelines doesn't replace the health worker — it removes the paperwork that keeps them away from patients. Multiply that across thousands of PHCs and you see why ministries of health and institutional funders are now talking to Qure.ai about population-scale deployments over existing national systems.
Honestly, what surprised me most is how little attention this got compared to the week's flashier AI headlines. A certification like this usually takes years and quietly changes what's possible for millions of patients. The frontier-model race gets the clicks; the regulatory grind gets the impact.
Key Takeaways
- Qure.ai's Aira has won Class IIb CE certification under the EU Medical Device Regulation
- Among the world's first AI CDSS to combine documentation, workflow automation, EHR analysis and decision support under one CE mark
- Built for frontline realities: local languages, existing devices, unreliable connectivity
- Qure.ai's portfolio is already live in 105+ countries with 26+ FDA-cleared findings
- Indian AI in healthcare is now competing — and winning — at global regulatory standards
Frequently Asked Questions
What is Qure.ai's Aira?
Aira is a clinical decision support system (CDSS) from Mumbai and New York-based Qure.ai. On September 18, 2026 it received Class IIb CE certification under the EU Medical Device Regulation.
Why is the Class IIb CE mark a big deal?
It places Aira among the world's first AI-powered CDSS to combine documentation, workflow automation, patient EHR analysis and clinical decision support under a single CE mark — a first for Indian AI in healthcare.
Where is Aira being used today?
Aira already runs at 10 pilot sites across Nigeria, Kenya, Mozambique, Solomon Islands and Bangladesh, while Qure.ai's wider portfolio is deployed in more than 105 countries with 26+ FDA-cleared findings.
What This Means for You
If you're a doctor, medical student or public health professional, AI tools like Aira will reach your workflow within a few years — understanding how to work alongside them is quickly becoming a career skill, not a curiosity. If you're a founder watching this space, note that the winning Indian healthtech products solve frontline friction (paperwork, language, connectivity), not just diagnosis. And if you want to build in this space, learning to direct today's AI tools properly is the first step — the GPT-6 Astra — Zero to Hero Guide covers prompting, AI agents, cost optimization and AI business ideas (healthcare included) in one structured ₹149 package.